Sculptor Capital LP Buys New Stake in Penumbra, Inc. $PEN

Sculptor Capital LP purchased a new position in shares of Penumbra, Inc. (NYSE:PEN) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 57,000 shares of the company’s stock, valued at approximately $17,998,000. Sculptor Capital LP owned about 0.14% of Penumbra at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in PEN. Royal Bank of Canada raised its position in shares of Penumbra by 35.8% during the 1st quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock worth $5,169,000 after acquiring an additional 5,092 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Penumbra by 209.1% in the second quarter. EverSource Wealth Advisors LLC now owns 272 shares of the company’s stock valued at $70,000 after purchasing an additional 184 shares in the last quarter. Cerity Partners LLC boosted its holdings in Penumbra by 22.3% in the second quarter. Cerity Partners LLC now owns 10,030 shares of the company’s stock valued at $2,574,000 after purchasing an additional 1,829 shares in the last quarter. California Public Employees Retirement System boosted its holdings in Penumbra by 7.9% in the second quarter. California Public Employees Retirement System now owns 61,027 shares of the company’s stock valued at $15,661,000 after purchasing an additional 4,491 shares in the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in Penumbra in the second quarter valued at approximately $1,137,000. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Stock Up 0.3%

Penumbra stock opened at $324.61 on Wednesday. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $362.41. The stock has a 50 day moving average of $320.38 and a two-hundred day moving average of $327.16. The company has a current ratio of 5.75, a quick ratio of 3.86 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $12.79 billion, a price-to-earnings ratio of 79.76, a PEG ratio of 2.01 and a beta of 0.70.

Penumbra (NYSE:PEN) last released its earnings results on Thursday, July 30th. The company reported $0.88 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.28). Penumbra had a net margin of 10.67% and a return on equity of 10.50%. The company had revenue of $390.05 million during the quarter, compared to analyst estimates of $389.64 million. During the same period in the previous year, the firm posted $0.86 EPS. The company’s revenue for the quarter was up 14.9% on a year-over-year basis. As a group, research analysts expect that Penumbra, Inc. will post 5.02 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PEN has been the topic of a number of research analyst reports. Zacks Research cut shares of Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Penumbra in a research report on Friday, July 17th. Royal Bank Of Canada restated a “sector perform” rating and issued a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Evercore reaffirmed an “outperform” rating and set a $320.00 price objective on shares of Penumbra in a report on Monday, July 6th. Finally, Wall Street Zen upgraded Penumbra to a “hold” rating in a research report on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $367.07.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.